Aurinia Pharmaceuticals (AUPH) Cost of Revenue (2021 - 2026)

Aurinia Pharmaceuticals' Cost of Revenue history runs 6 years deep, the most recent figure standing at $6.5 million for Q1 2026.

• Quarterly Cost of Revenue fell 24.13% year-over-year to $6.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $30.6 million (up 5.25% YoY) and the FY2025 annual result came in at $32.7 million, up 15.64% from the prior year.
• Cost of Revenue was $6.5 million for Q1 2026 at Aurinia Pharmaceuticals, down from $8.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $8.9 million in Q2 2024 and bottomed at $256000.0 in Q1 2022.
• A 5-year average of $5.1 million and a median of $6.0 million in 2024 frame the typical range for Cost of Revenue.
• Annual changes were most pronounced in 2024 — Cost of Revenue soared 1741.33% — and 2026, when it fell 24.13%.
• Aurinia Pharmaceuticals' Cost of Revenue stood at $1.4 million in 2022, then soared by 296.11% to $5.4 million in 2023, then advanced by 2.91% to $5.6 million in 2024, then surged by 58.48% to $8.8 million in 2025, then dropped by 26.07% to $6.5 million in 2026.
• Business Quant data shows AUPH's Cost of Revenue at $6.5 million in Q1 2026, $8.8 million in Q4 2025, and $8.2 million in Q3 2025.